Category: Health Science
-
![Xphyto’s (XPHY.C) COVID-screener: this bio-tech company ain’t spit-balling]()
Xphyto’s (XPHY.C) COVID-screener: this bio-tech company ain’t spit-balling
Xphyto’s test may be ideal to catch the super-spreaders – the infectious carriers blithely attending drumming circles because they feel healthy.
-
Revive Therapeutics (RVV.C) blasts off, up 68% after FDA Phase 3 COVID-19 approval
Formerly dismissed-by-many pharmaceutical company Revive Therapeutics (RVV.C) jumped a whopping 68% Friday upon revealing it has been granted approval to move forward with phase 3 clinical trials on the use of its Bucillamine medication as a potential treatment for patients with mild to moderate COVID-19. The U.S. Food and Drug Administration (FDA) has approved Revive…
-
Perimeter Medical Imaging AI: Covering the Margin Calls for Cancer
For the last eight months, the Covid-19 virus has been the centre of attention in the media, the markets, and the medical field. Collectively, countries, government agencies, academic institutions and pharmaceutical companies across the world have poured hundreds of millions into efforts combating the viral outbreak that has left so many countries and populations struggling…
-
Valeo Pharma Inc. (VPH.C) – THE undervalued biotech play
If you’re one of the discerning readers who bought Valeo Pharma’s stock since the last article I posted on July 6th, 2020: congratulations you should be making over 38% returns on your investment. Better yet, if you had bought Valeo’s stock a month ago, you would have been up close to 184%, which, y’know, is…
-
Perimeter Medical Imaging AI (PINK.V): They’re not curing cancer here, but they’ll help dig it out..
For the last eight months, the Covid-19 virus has been the center of attention in the media, the markets, and the medical field. Collectively, countries and government agencies, and academia, and pharmaceutical companies, have poured hundreds of millions into efforts combating the plague that has left so many countries and populations struggling, but despite the…
-
PredictMedix: Value Meets Growth
Technology is different from every other sector by virtue of one important factor – it scales. Because technology is scaleable, firms penetrate international markets easily, exercise greater pricing power, and capture bigger margins. Businesses exist to solve problems. In solving problems, they create value. Capturing that value, on the other hand, is independent of how…
-
ImmunoPrecise (IPA.V): when scientific breakthrough is executed strategically
You know what grinds my gears? The fact that investors will happily speculate on Tesla (TSLA.NYSE) stock because they think they understand the automobile market, but won’t attempt to do the due diligence for biotechs because it’s “too hard”.
-
Biotech: Who will survive when the Covid-19 Hype Ends? Part II
For part I of this series please click here. Cities across Canada are gradually returning to business as usual, and we’re winning the fight against Covid-19 (don’t look south of the border). Thanks to all citizens still wearing hats to hide their botched home-haircuts, and our essential workers who literally put their lives on the…
-
XPhyto (XPHY.C) advances a COVID-screener that works like a pregnancy test
“Visual confirmation of test results (probe activation) was observed in five to seven minutes,” states Xphyto.
-
Roadman Investments (LITT.V) really doesn’t want to talk about cedar leaf oil anymore
One of Roadman Investments (LITT.V) subsidiaries, CLOV Biopharma, recently completed its research program at UBC on cedar leaf oil vapour, but the Securities Exchange Commission (SEC) doesn’t care. The research program has taken a bit longer than the company would have liked, courtesy of COVID-19, but the company’s doctors have acquired most of the exemptions…
